Seeking Novel Therapeutics with Utility in CNS and PNS Indications

A publicly traded, fully integrated mid-cap biopharmaceutical company with commercial products providing aggregate >$1B annual revenue is seeking therapeutic candidates for use in CNS and PNS diseases. Novel therapeutics should be a new chemical entity, ideally with a composition of matter patent filed in the last 5 years or with potential to file a composition of matter patent or other similarly meaningful patent protection. Our client is a conscientious company looking to bring assets in house and develop them to their full potential. 

Approaches of Interest:

• Open to a range of neurological and psychiatric diseases 
• For neurodegenerative diseases, non-disease modifying therapeutics and treatments for management of neuropsychiatric symptoms (e.g. agitation/aggression, apathy, fatigue, psychosis) are also in scope 
• Modalities of interest include small molecules and peptides. Biologics and RNA-based therapies developed by biopharma companies are also of interest 
• Potential first-in-class therapeutics will be prioritized, potential best-in-class therapeutics will also be considered if strong rationale is provided 

Out of Scope:

• Therapeutics with disease-modifying action in neurodegenerative diseases or use in the following indications: nociceptive pain, MS, indications related to acute insult or injury (e.g. stroke, TBI), therapeutics with exclusive use in nicotine use disorder/ smoking cessation, diseases with less than 10,000 US patients 
• Repurposed/reformulated therapeutics 
• Diagnostics and medical devices 
• Digital therapeutics 

Developmental Stages of Interest:

• Opportunities that have a nominated drug candidate through to completion of Phase 1 are of interest, therapeutics that have at least in vivo validation are highest priority 

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Submissions should include the mechanism of action, biological rationale, a list of any validation work that has been completed, and patents that have been filed. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 

Opportunity for Partnership

Our client is open to a range of partnership opportunities, with the most appropriate structure being decided on a case-by-case basis. Example outcomes include asset acquisition and in-licensing assets, although more collaborative models are also a potential opportunity.